Cargando…

Detailed statistical analysis plan for the pulmonary protection trial

BACKGROUND: Pulmonary dysfunction complicates cardiac surgery that includes cardiopulmonary bypass. The pulmonary protection trial evaluates effect of pulmonary perfusion on pulmonary function in patients suffering from chronic obstructive pulmonary disease. This paper presents the statistical plan...

Descripción completa

Detalles Bibliográficos
Autores principales: Buggeskov, Katrine B, Jakobsen, Janus C, Secher, Niels H, Jonassen, Thomas, Andersen, Lars W, Steinbrüchel, Daniel A, Wetterslev, Jørn
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4307213/
https://www.ncbi.nlm.nih.gov/pubmed/25539792
http://dx.doi.org/10.1186/1745-6215-15-510
_version_ 1782354420738031616
author Buggeskov, Katrine B
Jakobsen, Janus C
Secher, Niels H
Jonassen, Thomas
Andersen, Lars W
Steinbrüchel, Daniel A
Wetterslev, Jørn
author_facet Buggeskov, Katrine B
Jakobsen, Janus C
Secher, Niels H
Jonassen, Thomas
Andersen, Lars W
Steinbrüchel, Daniel A
Wetterslev, Jørn
author_sort Buggeskov, Katrine B
collection PubMed
description BACKGROUND: Pulmonary dysfunction complicates cardiac surgery that includes cardiopulmonary bypass. The pulmonary protection trial evaluates effect of pulmonary perfusion on pulmonary function in patients suffering from chronic obstructive pulmonary disease. This paper presents the statistical plan for the main publication to avoid risk of outcome reporting bias, selective reporting, and data-driven results as an update to the published design and method for the trial. RESULTS: The pulmonary protection trial is a randomized, parallel group clinical trial that assesses the effect of pulmonary perfusion with oxygenated blood or Custodiol™ HTK (histidine-tryptophan-ketoglutarate) solution versus no pulmonary perfusion in 90 chronic obstructive pulmonary disease patients. Patients, the statistician, and the conclusion drawers are blinded to intervention allocation. The primary outcome is the oxygenation index from 10 to 15 minutes after the end of cardiopulmonary bypass until 24 hours thereafter. Secondary outcome measures are oral tracheal intubation time, days alive outside the intensive care unit, days alive outside the hospital, and 30- and 90-day mortality, and one or more of the following selected serious adverse events: pneumothorax or pleural effusion requiring drainage, major bleeding, reoperation, severe infection, cerebral event, hyperkaliemia, acute myocardial infarction, cardiac arrhythmia, renal replacement therapy, and readmission for a respiratory-related problem. CONCLUSIONS: The pulmonary protection trial investigates the effect of pulmonary perfusion during cardiopulmonary bypass in chronic obstructive pulmonary disease patients. A preserved oxygenation index following pulmonary perfusion may indicate an effect and inspire to a multicenter confirmatory trial to assess a more clinically relevant outcome. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT01614951, registered on 6 June 2012 ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/1745-6215-15-510) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-4307213
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-43072132015-01-28 Detailed statistical analysis plan for the pulmonary protection trial Buggeskov, Katrine B Jakobsen, Janus C Secher, Niels H Jonassen, Thomas Andersen, Lars W Steinbrüchel, Daniel A Wetterslev, Jørn Trials Update BACKGROUND: Pulmonary dysfunction complicates cardiac surgery that includes cardiopulmonary bypass. The pulmonary protection trial evaluates effect of pulmonary perfusion on pulmonary function in patients suffering from chronic obstructive pulmonary disease. This paper presents the statistical plan for the main publication to avoid risk of outcome reporting bias, selective reporting, and data-driven results as an update to the published design and method for the trial. RESULTS: The pulmonary protection trial is a randomized, parallel group clinical trial that assesses the effect of pulmonary perfusion with oxygenated blood or Custodiol™ HTK (histidine-tryptophan-ketoglutarate) solution versus no pulmonary perfusion in 90 chronic obstructive pulmonary disease patients. Patients, the statistician, and the conclusion drawers are blinded to intervention allocation. The primary outcome is the oxygenation index from 10 to 15 minutes after the end of cardiopulmonary bypass until 24 hours thereafter. Secondary outcome measures are oral tracheal intubation time, days alive outside the intensive care unit, days alive outside the hospital, and 30- and 90-day mortality, and one or more of the following selected serious adverse events: pneumothorax or pleural effusion requiring drainage, major bleeding, reoperation, severe infection, cerebral event, hyperkaliemia, acute myocardial infarction, cardiac arrhythmia, renal replacement therapy, and readmission for a respiratory-related problem. CONCLUSIONS: The pulmonary protection trial investigates the effect of pulmonary perfusion during cardiopulmonary bypass in chronic obstructive pulmonary disease patients. A preserved oxygenation index following pulmonary perfusion may indicate an effect and inspire to a multicenter confirmatory trial to assess a more clinically relevant outcome. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT01614951, registered on 6 June 2012 ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/1745-6215-15-510) contains supplementary material, which is available to authorized users. BioMed Central 2014-12-23 /pmc/articles/PMC4307213/ /pubmed/25539792 http://dx.doi.org/10.1186/1745-6215-15-510 Text en © Buggeskov et al.; licensee BioMed Central. 2014 This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Update
Buggeskov, Katrine B
Jakobsen, Janus C
Secher, Niels H
Jonassen, Thomas
Andersen, Lars W
Steinbrüchel, Daniel A
Wetterslev, Jørn
Detailed statistical analysis plan for the pulmonary protection trial
title Detailed statistical analysis plan for the pulmonary protection trial
title_full Detailed statistical analysis plan for the pulmonary protection trial
title_fullStr Detailed statistical analysis plan for the pulmonary protection trial
title_full_unstemmed Detailed statistical analysis plan for the pulmonary protection trial
title_short Detailed statistical analysis plan for the pulmonary protection trial
title_sort detailed statistical analysis plan for the pulmonary protection trial
topic Update
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4307213/
https://www.ncbi.nlm.nih.gov/pubmed/25539792
http://dx.doi.org/10.1186/1745-6215-15-510
work_keys_str_mv AT buggeskovkatrineb detailedstatisticalanalysisplanforthepulmonaryprotectiontrial
AT jakobsenjanusc detailedstatisticalanalysisplanforthepulmonaryprotectiontrial
AT sechernielsh detailedstatisticalanalysisplanforthepulmonaryprotectiontrial
AT jonassenthomas detailedstatisticalanalysisplanforthepulmonaryprotectiontrial
AT andersenlarsw detailedstatisticalanalysisplanforthepulmonaryprotectiontrial
AT steinbrucheldaniela detailedstatisticalanalysisplanforthepulmonaryprotectiontrial
AT wetterslevjørn detailedstatisticalanalysisplanforthepulmonaryprotectiontrial